List of patents in the Dermatology industry

Patents where

Current Assignee

Industry

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10308644 Heterocyclic compounds as immunomodulators	Patent 10308644 was granted and assigned to Incyte on June, 2019 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	10308644	June 4, 2019
‌ US Patent 11866434 Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof	Patent 11866434 was granted and assigned to Incyte on January, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11866434	January 9, 2024
‌ US Patent 11866451 Salts and crystalline forms of a PD-1/PD-L1 inhibitor	Patent 11866451 was granted and assigned to Incyte on January, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11866451	January 9, 2024
‌ US Patent 11760756 Crystalline form of a PD-1/PD-L1 inhibitor	Patent 11760756 was granted and assigned to Incyte on September, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11760756	September 19, 2023
‌ US Patent 11780836 Process of preparing a PD-1/PD-L1 inhibitor	Patent 11780836 was granted and assigned to Incyte on October, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11780836	October 10, 2023
‌ US Patent 12024517 Salts of an FGFR inhibitor	Patent 12024517 was granted and assigned to Incyte on July, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	12024517	July 2, 2024
‌ US Patent 11753406 Salts of a PD-1/PD-L1 inhibitor	Patent 11753406 was granted and assigned to Incyte on September, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11753406	September 12, 2023
‌ US Patent 11421349 Photoactivatable fibers and fabric media	Patent 11421349 was granted and assigned to Klox Technologies on August, 2022 by the United States Patent and Trademark Office.	Klox Technologies	Klox Technologies	United States Patent and Trademark Office	11421349	August 23, 2022
‌ US Patent 11471695 Device for targeted treatment of dermatoses	Patent 11471695 was granted and assigned to Strata Skin Sciences on October, 2022 by the United States Patent and Trademark Office.	Strata Skin Sciences	Strata Skin Sciences	United States Patent and Trademark Office	11471695	October 18, 2022
‌ US Patent 11446272 BPO wash emulsion composition	Patent 11446272 was granted and assigned to Galderma on September, 2022 by the United States Patent and Trademark Office.		Galderma	United States Patent and Trademark Office	11446272	September 20, 2022
‌ US Patent 11407750 Derivatives of an FGFR inhibitor	Patent 11407750 was granted and assigned to Incyte on August, 2022 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11407750	August 9, 2022
‌ US Patent 7598257 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors	Patent 7598257 was granted and assigned to Incyte on October, 2009 by the United States Patent and Trademark Office.		Incyte	United States Patent and Trademark Office	7598257	October 6, 2009
‌ US Patent 11364214 Compositions and methods for treating eczema	Patent 11364214 was granted and assigned to Dermala on June, 2022 by the United States Patent and Trademark Office.	Dermala	Dermala	United States Patent and Trademark Office	11364214	June 21, 2022
‌ US Patent 11905292 Process and intermediates for preparing a JAK inhibitor	Patent 11905292 was granted and assigned to Incyte on February, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11905292	February 20, 2024
‌ US Patent 11147790 Treatment of cutaneous disorders	Patent 11147790 was granted and assigned to Verrica Pharmaceuticals on October, 2021 by the United States Patent and Trademark Office.	Verrica Pharmaceuticals	Verrica Pharmaceuticals	United States Patent and Trademark Office	11147790	October 19, 2021
‌ US Patent 11780840 Tricyclic urea compounds as JAK2 V617F inhibitors	Patent 11780840 was granted and assigned to Incyte on October, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11780840	October 10, 2023
‌ US Patent 11466004 Solid forms of an FGFR inhibitor and processes for preparing the same	Patent 11466004 was granted and assigned to Incyte on October, 2022 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11466004	October 11, 2022
‌ US Patent 11331257 Biophotonic compositions and methods for providing biophotonic treatment		Klox Technologies	Klox Technologies	United States Patent and Trademark Office	11331257	May 17, 2022
‌ US Patent 8980905 Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors	Patent 8980905 was granted and assigned to Leo Pharma on March, 2015 by the United States Patent and Trademark Office.		Leo Pharma	United States Patent and Trademark Office	8980905	March 17, 2015
‌ US Patent 11590149 Compositions and methods for treating acne vulgaris		Dermala	Dermala	United States Patent and Trademark Office	11590149	February 28, 2023
‌ US Patent 11376369 Syringe			Galderma	United States Patent and Trademark Office	11376369	July 5, 2022
‌ US Patent 11052064 Compositions, methods and systems for the treatment of cutaneous disorders	Patent 11052064 was granted and assigned to Verrica Pharmaceuticals on July, 2021 by the United States Patent and Trademark Office.	Verrica Pharmaceuticals	Verrica Pharmaceuticals	United States Patent and Trademark Office	11052064	July 6, 2021
‌ US Patent 11472801 Crystalline forms of a FGFR inhibitor and processes for preparing the same	Patent 11472801 was granted and assigned to Incyte on October, 2022 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11472801	October 18, 2022
‌ US Patent 11643509 Carbohydrate crosslinker	Patent 11643509 was granted and assigned to Galderma on May, 2023 by the United States Patent and Trademark Office.	Galderma	Galderma	United States Patent and Trademark Office	11643509	May 9, 2023
‌ US Patent 11014923 Bicyclic heterocycles as FGFR4 inhibitors	Patent 11014923 was granted and assigned to Incyte on May, 2021 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11014923	May 25, 2021

...

Results per page:

582 results

0 selected

582 results

0 selected